The synthetic biology company CellX has recently secured tens of millions of RMB in Series A+ financing with the involvement of multiple strategic investors. The funds will primarily be allocated towards advancing industrialization efforts, which include the construction of a pilot plant with a capacity of thousands of liters, procurement of essential equipment, and research and development for the industrialization of the technology.

This funding round follows CellX's previous Series A financing in the first half of 2022, which raised nearly 100 million RMB.

Founded in 2020 and headquartered in Shanghai, CellX is a synthetic biology technology company that specializes in the development of novel protein products centered around cultured meat. By leveraging advanced interdisciplinary innovations in life sciences and food sciences, CellX aims to redefine the models of food production and consumption. Reports indicate that CellX has established four major technological platforms, encompassing cell lines, culture medium, innovative processes, and innovative products.

Earlier this year, the company unveiled its plan to construct China's first pilot plant for cultured meat, boasting a capacity of thousands of liters. The facility will be equipped with a digital and intelligent equipment management system, housing multiple bioreactors of considerable volume. CellX will employ its proprietary suspension culture technology and serum-free culture medium for the pilot production of cultured meat. Furthermore, the space will provide an interactive experience for consumers, enabling direct visits and product sampling. With a vision to create China's inaugural "transparent food space," CellX is dedicated to integrating technology research and development, pilot production, and interactive experiences.

Disclaimer: Despite our efforts to maintain accuracy, errors are unavoidable due to our limited expertise. Some information may not be up to date, and we welcome your feedback to make necessary corrections. This document is intended solely for the purpose of providing a business-oriented and written introduction to the field of synthetic biology. It does not constitute any investment advice. We appreciate your understanding.